Medipattern's B-CADTM Version 2 Shown To Increase Diagnostic Accuracy By 44% In Lesions Less Than 1 Cm In Size
The study was conducted at the PLA301 Hospital in Beijing, PRC and is based upon 100 confirmed biopsied cases, comparing the diagnostic accuracy of three reading scenarios: a single physician, double reading with two physicians and a single physician reading with B-CAD. The accuracy of the single physician increased with B-CAD in all categories. The most striking result shows a statistically significant 44 percent improvement in diagnostic accuracy for the single reader with B-CAD v2 on lesions less than 1 cm in size (n equals 9).
"The Value of Computer-Aided Detection for Breast Ultra-Sonography (B-CAD) in the Diagnosis of Breast Cancer" by Dr. Li and Dr. Xu will be shared at the 18th annual conference of the National Consortium of Breast Centers (NCBC) which takes place March 1 to March 5, 2008 in Las Vegas. Each year participants are invited to submit an abstract in an effort to share research, programs, and results with the goal of facilitating communication among breast care centers and individual members. This is a unique opportunity to interact with dedicated professionals in breast care and the NCBC represents the only forum of its kind in Multidisciplinary Breast Care.
"Finding small cancers is a particularly important part of our overall goal to find cancer in its earliest stage while it is still treatable. Yet small cancers present doctors with their greatest challenge as it is one of the main reasons for misdiagnosis. B-CAD can assist doctors in focusing on these easily overlooked important details and increase the detection rate of small breast cancers." Dr. Li notes in the paper, "The study also finds that CAD is a very useful tool for China's current needs; a single doctor with B-CAD can perform as well as two doctors reading together. A single doctor with B-CAD is far more efficient and economical than using our limited skilled resources for double reading."
The physicians were not aware of the pathology outcomes when reading. The cases were separated into three size categories, malignant cancers greater than 2 cm, ranging from 1 to 2 cm and less than 1 cm. The cases were evaluated using the American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS(R)) Lexicon. Doctors reading without B-CAD used the lexicon to characterize the lesions in the study and assess the diagnosis. B-CAD automatically finds the edge of the lesion and uses this information to characterize the lesion for the physician. B-CAD further consolidates the information into a detailed report documenting whether the lesion is probably benign or probably malignant.
Dr. Li and Dr. Xu continue, "In conclusion, B-CAD has been shown to correctly identify potentially malignant lesions with a high degree of sensitivity, particularly for less than 1 cm breast cancers. B-CAD improved the accuracy using the ACR BI-RADS assessment. Therefore, doctors should analyze ultrasonic images of breast lesions assisted by B-CAD, and then the doctor should judge the suspicious sites identified with B-CAD and make the diagnostic decision using their own clinical experience. This will increase the detection rate of breast cancer and reduce the false negative rate. CAD is a valuable tool assisting the doctor when reading breast ultrasound imaging."
"We are very pleased with the results of the China study as they further demonstrate the value of B-CAD v2, which is currently available outside of the United States, in making doctors more efficient and effective in the detection and diagnosis of breast cancer," stated Jeff Collins, president and CEO of Medipattern. "China represents a significant market for Medipattern as the incidence of breast cancer has risen dramatically over the past 20 years. Using B-CAD as a standard procedure with breast ultrasound will help boost the efficiency of the system and the doctors. Many studies have shown that ultrasound is more effective in cancer detection than mammograms in cases of dense breast tissue, which is very typical in Chinese women. We expect sales of B-CAD to commence once final approval from China's State Food and Drug Administration is obtained."
Medipattern would like to announce that it has appointed Kevin O'Connor and Ali Mahdavi of Genoa Management Limited ("Genoa") of Toronto, as its investor relations advisors and independent capital markets counsel. Genoa's mandate will focus on developing and expanding the network of investors, analysts, and financial intermediaries who are interested in following the Medipattern investment story.
Upcoming Events:
Medipattern will participate in the following events:
- European Congress of Radiology (ECR), March 7 to 11, Vienna, Austria
- American Institute of Ultrasound in Medicine (AIUM) Annual Meeting, March 12 to 15, San Diego, CA. USA
- Ultrasound Woman's Imaging Conference, April 3 to 6, Boston, MA USA
- China Med Conference, April 10 to 15, Beijing, PRC
- The Breast Course, April 13 to 16, Quebec City, Quebec, Canada
- American Society of Breast Surgeons (ASBS) Annual Meeting, April 30 to May 4, New York City, NY USA
- 33rd National Conference on Breast Cancer, American College of Radiology (ACR) Society of Breast Imaging (SBI), May 8 to 10, Orlando FL, USA
- Radiological Society of North America (RSNA), November 30 to December 5, Chicago, IL, USA
The Medipattern Corporation
Medipattern develops computer-aided detection (CAD) solutions for medical imaging. These products enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD(TM) for breast ultrasound and B-CADMRI(TM). Both have received awards for innovation in the industry. The B-CAD products, part of the Company's CADENZA(TM) platform, use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in medical images. Please visit the company's website at: http://www.medipattern.com.
B-CAD(TM) and B-CADMRI(TM) are trademarks of The Medipattern Corporation. Medipattern(R) is a registered mark of The Medipattern Corporation.
Forward-looking statements
This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates,'' "believes,'' "estimates,'' "expects,'' "plans,'' "intends,'' "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at http://www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.
The Medipattern Corporation
Medipattern's B-CADTM versiunea 2 dovedit a creºte diagnostic de precizie de 44% a leziunilor în mai puþin de 1 cm - Medipattern's B-CADTM Version 2 Shown To Increase Diagnostic Accuracy By 44% In Lesions Less Than 1 Cm In Size - articole medicale engleza - startsanatate